Guidelines Waldenström’s macroglobulinaemia (WM)

This is a promotional website intended for healthcare professionals in the UK and Ireland only.

After a confirmed diagnosis of Waldenström’s macroglobulinemia (WM), an assessment of burden of disease and screening for complications is recommended to inform if there is an indication for therapy (Figure 1).1

Figure 1. BSH treatment algorithm.1

ASCT, autologous stem cell transplant; BSH, British Society for Haematology; BTKi, Bruton’s tyrosine kinase inhibitors; CAD, cold agglutinin disease, CNS, central nervous system; DRC, dexamethasone, rituximab and cyclophosphamide; IgM, immunoglobulin M; ISSWM, International Scoring System for Waldenström’s macroglobulinemia; PCNSL, primary central nervous system lymphoma; Pl, proteasome inhibitor. Adapted from Pratt G, et al. Br J Haematol. 2022.1

Treatment options for frontline therapy*:1

  • BTK inhibitor +/- rituximab
  • Dexamethasone, rituximab, cyclophosphamide (DRC)
  • Proteasome inhibitor-containing regimen
  • Rituximab-bendamustine (BR)

Treatment options for relapsed/refractory therapy:1

  • As above – choice of therapy is dependent on previous therapies, time from prior therapy and patient factors

According to NICE guidance, BRUKINSA®▼ is recommended as a treatment option for WM in adults in the UK who have had at least one treatment, and only if bendamustine plus rituximab is also suitable.2

According to SMC guidance, BRUKINSA is accepted for use within NHS Scotland in line with its indication (for adult patients with WM who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemotherapy).3

The Health Service Executive (HSE) in Ireland has also approved reimbursement for BRUKINSA for the treatment of adult patients with WM who have received at least one prior therapy, or as first-line treatment for patients unsuitable for chemo-immunotherapy.4

*The BSH guidelines are based on published evidence rather than what is funded in the UK.1 Listed in alphabetical order rather than order of preference.1 Choice of therapy will be partly based on indication for therapy and speed with which disease burden or IgM paraprotein needs to be reduced.1


Abbreviations: BSH, British Society for Haematology; BTK, Bruton’s tyrosine kinase inhibitor; IgM, immunoglobulin M; NICE, National Institute of Health and Care Excellence; SMC, Scottish Medicines Consortium.

Adverse events should be reported

United Kingdom (incl. Northern Ireland): Healthcare Professionals are asked to report any suspected adverse reactions via Yellow Card Scheme found at www.mhra.gov.uk/yellowcard.
Ireland: Healthcare Professionals are asked to report any suspected adverse reactions via HPRA.

All adverse events (UK and Ireland) should also be reported to BeiGene at [email protected]; (UK: 08009176799; Ireland: 1800812061).

For medical information, please contact: UK: 08004320266, Ireland: 1800946589 or email: [email protected]

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

September 2023 [0823-BRU-PRC-169]

Back to top

Brukinsa®▼ UK and Ireland healthcare professional website

This website contains information on BRUKINSA (zanubrutinib) and is intended for healthcare professionals in the UK and Ireland only.

To direct you to the most appropriate information, please confirm you are a UK or Ireland Healthcare Professional.

If you are not a UK or Ireland Healthcare Professional, you will be directed to the BRUKINSA Patient Information leaflet.

Are you a UK or Ireland Healthcare Professional?

0823-BRU-PRC-184 | September 2023

No, I am not